GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucid Diagnostics Inc (NAS:LUCD) » Definitions » Debt-to-EBITDA

Lucid Diagnostics (Lucid Diagnostics) Debt-to-EBITDA : -0.37 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Lucid Diagnostics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lucid Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $15.06 Mil. Lucid Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.20 Mil. Lucid Diagnostics's annualized EBITDA for the quarter that ended in Dec. 2023 was $-40.76 Mil. Lucid Diagnostics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.37.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Lucid Diagnostics's Debt-to-EBITDA or its related term are showing as below:

LUCD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.31   Med: -0.17   Max: -0.04
Current: -0.31

During the past 5 years, the highest Debt-to-EBITDA Ratio of Lucid Diagnostics was -0.04. The lowest was -0.31. And the median was -0.17.

LUCD's Debt-to-EBITDA is ranked worse than
100% of 431 companies
in the Medical Devices & Instruments industry
Industry Median: 1.25 vs LUCD: -0.31

Lucid Diagnostics Debt-to-EBITDA Historical Data

The historical data trend for Lucid Diagnostics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucid Diagnostics Debt-to-EBITDA Chart

Lucid Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
- - - -0.04 -0.31

Lucid Diagnostics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.22 -0.32 -0.30 -0.37

Competitive Comparison of Lucid Diagnostics's Debt-to-EBITDA

For the Medical Devices subindustry, Lucid Diagnostics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucid Diagnostics's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lucid Diagnostics's Debt-to-EBITDA falls into.



Lucid Diagnostics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lucid Diagnostics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(15.056 + 0.199) / -49.751
=-0.31

Lucid Diagnostics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(15.056 + 0.199) / -40.76
=-0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Lucid Diagnostics  (NAS:LUCD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Lucid Diagnostics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lucid Diagnostics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucid Diagnostics (Lucid Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Executives
Stanley Lapidus director 101 HARTWELL AVE., LEXINGTON MA 02421
Debra White director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Michael Adam Gordon officer: General Counsel ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil officer: Chief Operating Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Pavmed Inc. 10 percent owner 360 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10017
Lishan Aklog director, officer: Chief Executive Officer 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Dennis M Mcgrath officer: Chief Financial Officer C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Ronald M Sparks director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
James L Cox director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Aster Angagaw director 150 PEABODY PLACE, MEMPHIS TN 38103
Jacque J Sokolov director
David F Wurtman officer: Chief Medical Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165